Axsome Therapeutics Price Target Cut to $220.00/Share From $246.00 by Baird

What happened

Baird cut its price target on Axsome Therapeutics to $220.00 per share from $246.00 while keeping an Outperform rating, which means Baird still expects the stock to do better than the average stock it covers.

Confirmed

Global impact / market context

A lower price target means Baird expects less upside, though Outperform signals continued confidence. For investors, the gap between the old and new target shows how analyst expectations shift after new information, even when the overall positive view is unchanged.

Analyst inference

Analyst price targets are estimates, not guarantees, and often move after earnings or drug trial news. A cut paired with an unchanged Outperform rating suggests a recalibration of expected gains rather than a negative view on Axsome's drug pipeline or revenue prospects.

Analyst inference

What to watch

1. Baird's $220.00 target and Outperform rating are the only analyst details supplied, so watch whether other firms issue similar target changes for Axsome. Confirmed
2. Investors should compare the new target with Axsome's current share price to see how much upside Baird still sees, since the article gives no current price. Proposed
3. Watch for Axsome announcements on drug trial results or sales that could explain why Baird trimmed its target while keeping its positive Outperform rating. Analyst inference

Evidence

• Original source link unavailable